We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
+50.65%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.42B
AUM Growth
+$1.85B
(+52%)
Cap. Flow
+$509M
Cap. Flow
% of AUM
9.4%
Top 10 Holdings %
Top 10 Hldgs %
46.89%
Holding
89
New
20
Increased
11
Reduced
36
Closed
9
Top Buys
| 1 |
ADC Therapeutics
ADCT
|
+$210M |
| 2 |
BioNTech
BNTX
|
+$145M |
| 3 |
IMMU
Immunomedics Inc
IMMU
|
+$102M |
| 4 |
Pliant Therapeutics
PLRX
|
+$90.5M |
| 5 |
RPTX
Repare Therapeutics
RPTX
|
+$76.6M |
Top Sells
| 1 |
Biogen
BIIB
|
+$128M |
| 2 |
uniQure
QURE
|
+$90.1M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$75.7M |
| 4 |
Tandem Diabetes Care
TNDM
|
+$56.7M |
| 5 |
Centene
CNC
|
+$49M |
Sector Composition
| 1 | Healthcare | 93.05% |
| 2 | Industrials | 1.02% |
| 3 | Financials | 0.23% |
| 4 | Technology | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Sanofi
SNY
$105B
| $62.6M | 1.16% |
+1,225,500
| New | +$59.6M |
|
27
Stoke Therapeutics
STOK
$1.87B
| $59.6M | 1.1% |
2,502,306
+336,368
| +16% | +$7.99M |
|
|
NVRO
28
DELISTED
NEVRO CORP.
NVRO
| $59.5M | 1.1% |
497,764
-208,662
| -30% | -$24.7M |
|
29
Krystal Biotech
KRYS
$10.2B
| $58.4M | 1.08% |
1,409,745
+357,945
| +34% | +$17.2M |
|
|
TCDA
30
DELISTED
Tricida, Inc. Common Stock
TCDA
| $58.2M | 1.08% |
2,119,000
-7,600
| -0.4% | -$207K |
|
|
31
uniQure
QURE
$2.81B
| $56.2M | 1.04% |
1,247,135
-1,526,390
| -55% | -$90.1M |
|
|
IMGN
32
DELISTED
Immunogen Inc
IMGN
| $55.2M | 1.02% |
12,006,979
-4,726,900
| -28% | -$20.1M |
|
33
CryoPort
CYRX
$832M
| $55M | 1.02% |
1,817,663
| – | – |
|
34
Scholar Rock
SRRK
$6.44B
| $52.4M | 0.97% |
2,875,889
-14,200
| -0.5% | -$242K |
|
|
PPD
35
DELISTED
PPD, Inc. Common Stock
PPD
| $51.8M | 0.96% |
1,933,473
+642,641
| +50% | +$16.1M |
|
|
AMED
36
DELISTED
Amedisys
AMED
| $44.9M | 0.83% |
226,165
+48,600
| +27% | +$9.06M |
|
|
DVAX
37
DELISTED
Dynavax Technologies
DVAX
| $44.9M | 0.83% |
+5,062,100
| New | +$25.6M |
|
|
38
Biogen
BIIB
$29.2B
| $43.4M | 0.8% |
162,300
-427,000
| -72% | -$128M |
|
|
AXNX
39
DELISTED
Axonics, Inc. Common Stock
AXNX
| $41.9M | 0.77% |
1,192,100
-315,300
| -21% | -$10.9M |
|
40
Merck
MRK
$305B
| $40.5M | 0.75% |
549,466
-276,882
| -34% | -$20.8M |
|
41
DexCom
DXCM
$28.4B
| $39.4M | 0.73% |
389,200
-128,000
| -25% | -$11.4M |
|
42
Novartis
NVS
$289B
| $38.4M | 0.71% |
439,800
-213,800
| -33% | -$18.5M |
|
43
ICU Medical
ICUI
$3.97B
| $37.1M | 0.69% |
+201,400
| New | +$40M |
|
44
Genmab
GMAB
$17.9B
| $35.8M | 0.66% |
1,057,393
-491,607
| -32% | -$13.4M |
|
45
Boston Scientific
BSX
$64.5B
| $31.5M | 0.58% |
+897,355
| New | +$32.3M |
|
46
UnitedHealth
UNH
$381B
| $30.6M | 0.57% |
103,900
-137,200
| -57% | -$39.3M |
|
|
CTLT
47
DELISTED
CATALENT, INC.
CTLT
| $30.3M | 0.56% |
413,100
-93,200
| -18% | -$6.33M |
|
|
LMNX
48
DELISTED
Luminex Corp
LMNX
| $29.9M | 0.55% |
+917,907
| New | +$29M |
|
|
EIDX
49
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| $28.3M | 0.52% |
593,842
-95,636
| -14% | -$4.45M |
|
50
Zymeworks
ZYME
$1.81B
| $28.3M | 0.52% |
783,500
-85,100
| -10% | -$3.13M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO